New IPF pill HEC585 enters Mid-Stage trial
NCT ID NCT05060822
First seen Apr 22, 2026 · Last updated May 22, 2026 · Updated 8 times
Summary
This study tests an experimental drug called HEC585 in 270 adults with idiopathic pulmonary fibrosis (IPF), a serious lung disease. Participants receive either HEC585, a placebo, or an active comparator (pirfenidone) to see if the drug improves lung function over 24 weeks. The goal is to find a safe and effective dose that slows disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.